Media Release New data at the ASCO20 Virtual Scientific Program reflects Roche’s commitment to accelerating progress in cancer care First clinical data from tiragolumab, Roche’s novel anti-TIGIT cancer immunotherapy, in combination with Tecentriq® (atezolizumab) in patients with PD-L1-positive metastatic non- small cell lung cancer (NSCLC) Updated overall survival data for Alecensa® (alectinib), in people living with anaplastic lymphoma kinase (ALK)-positive metastatic NSCLC Key highlights to be shared on Roche’s ASCO virtual newsroom, 29 May 2020, 08:00 CEST Basel, 7 May 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from clinical trials of 19 approved and investigational medicines across 21 cancer types, will be presented at the ASCO20 Virtual Scientific Program organised by the American Society of Clinical Oncology (ASCO), which will be held 29-31 May, 2020. A total of 120 abstracts that include a Roche medicine will be presented at this year's meeting. "At ASCO, we will present new data from many investigational and approved medicines across our broad oncology portfolio," said Levi Garraway, M.D., Ph.D., Roche's Chief Medical Officer and Head of Global Product Development. “These efforts exemplify our long-standing commitment to improving outcomes for people with cancer, even during these unprecedented times. By integrating our medicines and diagnostics together with advanced insights and novel platforms, Roche is uniquely positioned to deliver the healthcare solutions of the future." Together with its partners, Roche is pioneering a comprehensive approach to cancer care, combining new diagnostics and treatments with innovative, integrated data and access solutions for approved medicines that will both personalise and transform the outcomes of people affected by this deadly disease. Key presentations First results of tiragolumab, Roche’s novel cancer immunotherapy designed to bind to TIGIT, will be shared. These results, from the phase II CITYSCAPE study, examine tiragolumab in combination with Tecentriq® (atezolizumab) compared with Tecentriq alone as an initial treatment for people with PD-L1-positive locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC). In addition, updated five-year overall survival rates with Alecensa® (alectinib) in people living with treatment-naive anaplastic lymphoma kinase (ALK)-positive metastatic/advanced NSCLC will be presented. With five approved lung cancer medicines and an extensive pipeline across multiple subtypes, Roche's ultimate aim is to provide an effective treatment option for each person diagnosed with the disease, tailored to the unique characteristics of their tumours. Studies featured from partnerships with Flatiron Health and Foundation Medicine demonstrate how the use of next-generation sequencing (NGS) may help inform treatment decisions, optimise testing and enable F. Hoffmann-La Roche Ltd 4070 Basel Group Communications Tel. +41 61 688 88 88 Switzerland Roche Group Media Relations www.roche.com 1/6 personalised therapy, including an ongoing additional study designed to prospectively link longitudinal, real- world clinical data with genomic, imaging and outcomes data for patients with advanced lung cancers. The study is monitoring circulating tumour DNA (ctDNA) using FoundationOne® Liquid, and tumour tissue samples will be genomically profiled using FoundationOne® CDx. Based on this year’s virtual format, Roche will be launching a virtual newsroom for journalists to access further information on our contribution to the ASCO20 Virtual Scientific Program, as well as the latest innovations and developments in Roche’s approach to accelerating progress in cancer care. The newsroom will be available on Friday 29 May, 08:00 CEST, and open to journalists from outside the United States. To access Roche’s ASCO virtual newsroom, please register via this link: https://asco2020media.roche.com Follow Roche on Twitter via @Roche and keep up to date with ASCO news and updates by using the hashtag #ASCO20. Overview of key presentations featuring Roche medicines at ASCO 2020 Medicine Abstract title Abstract number Lung cancer Tiragolumab Primary analysis of a randomized, double-blind, phase II #9503 study of the anti-TIGIT antibody tiragolumab (tira) plus Oral abstract session atezolizumab (atezo) versus placebo plus atezo as first- line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE) Alecensa Updated overall survival (OS) and safety data from the #9518 (alectinib) randomized, phase III ALEX study of alectinib (ALC) Poster: 284 versus crizotinib (CRZ) in untreated advanced ALK+ Poster discussion NSCLC session Tecentriq Patient-reported outcomes (PROs) in the randomized, #9594 (atezolizuma phase III IMpower110 study of atezolizumab (atezo) vs Poster: 360 b) chemotherapy in 1L metastatic NSCLC Poster session Tecentriq IMpower150: exploratory analysis of brain metastases #9587 development Poster: 353 Poster session Tecentriq IMpower150: exploratory efficacy analysis in patients N/A (pts) with bulky disease e-publication 2/6 Flatiron Health data in lung cancer Real World A multi-stakeholder platform to prospectively link #TPS2087 Data longitudinal real-world clinico-genomic, imaging, and Poster: 79 outcomes data for patients with metastatic lung cancer Poster session Real World Genomic testing among patients (pts) with newly #9592 Data diagnosed advanced non-small cell lung cancer Poster: 358 (aNSCLC) in the United States: a contemporary clinical Poster session practice patterns study Solid tumours Rozlytrek Updated entrectinib data in children and adolescents #107 (entrectinib) with recurrent or refractory solid tumors, including Clinical science primary CNS tumor symposium Rozlytrek Efficacy and safety of entrectinib in patients (pts) with #3605 NTRK-Fusion-Positive (NTRK-fp) solid tumors: An Poster: 335 updated integrated analysis Poster session Genitourinary and gastrointestinal cancers Tecentriq IMvigor010: primary analysis from a phase III #5000 randomized study of adjuvant atezolizumab (atezo) Oral abstract session versus observation (obs) in high-risk muscle-invasive urothelial carcinoma (MIUC) Tecentriq Tumor, immune, and stromal characteristics associated #5011 with clinical outcomes with atezolizumab (atezo) + Clinical science platinum-based chemotherapy (PBC) or atezo symposium monotherapy (mono) versus PBC in metastatic urothelial cancer (mUC) from the phase III IMvigor130 study Tecentriq Phase Ib/II open-label, randomized evaluation of 2L #4540 atezolizumab + PEGPH20 versus control in Poster: 148 MORPHEUS-pancreatic ductal adenocarcinoma (M- Poster session PDAC) and MORPHEUS-gastric cancer (M-GC) Tecentriq, Complete responses (CR) in patients receiving #4596 Avastin atezolizumab (atezo) + bevacizumab (bev) vs sorafenib Poster: 204 (bevacizuma (sor) in IMbrave150: a phase III clinical trial for Poster session b) unresectable hepatocellular carcinoma (HCC) 3/6 Ipatasertib Circulating tumor DNA (ctDNA) dynamics associate #5508 with treatment response and radiological progression- Oral abstract session free survival (rPFS): Analyses from a randomized phase II trial in metastatic castration-resistant prostate cancer (mCRPC) Blood cancer Venclexta Impact of premature venetoclax (Ven) #8028 (venetoclax) discontinuation/interruption on outcomes in Poster: 361 relapsed/refractory (R/R) chronic lymphocytic leukemia Poster session (CLL): Phase III MURANO study results Venclexta, Fixed-duration venetoclax-obinutuzumab for previously #8027 Gazyva untreated patients with chronic lymphocytic leukemia: Poster: 360 (obinutuzum follow-up of efficacy and safety results from the Poster session ab) multicenter, open-label, randomized, phase III CLL14 trial Gazyva Comparison of efficacy and safety with obinutuzumab #8023 plus chemotherapy versus rituximab plus chemotherapy Poster: 356 in patients with previously untreated follicular Poster session lymphoma – Updated results from the phase III Gallium Study Breast cancer Kadcyla Primary analysis of KAITLIN: A phase III study of #500 (trastuzuma trastuzumab emtansine (T-DM1) + pertuzumab versus Oral abstract session b trastuzumab + pertuzumab + taxane, after anthracyclines emtansine), as adjuvant therapy for high-risk HER2-positive early Perjeta breast cancer (EBC) (pertuzumab ) Kadcyla Biomarker data from KATHERINE: A phase III study of #502 adjuvant trastuzumab emtansine (T-DM1) versus Oral abstract session trastuzumab (H) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer About Roche in Oncology Roche has been working to transform cancer care for more than 50 years, bringing the first specifically designed anti-cancer chemotherapy drug, fluorouracil, to patients in 1962. Roche’s commitment to 4/6 developing innovative medicines and diagnostics for cancers remains steadfast. The Roche Group’s portfolio of innovative cancer medicines includes: Alecensa® (alectinib); Avastin® (bevacizumab); Cotellic® (cobimetinib); Erivedge® (vismodegib); Gazyva®/Gazyvaro® (obinutuzumab); Herceptin® (trastuzumab); Kadcyla® (trastuzumab emtansine); MabThera®/Rituxan® (rituximab); Perjeta® (pertuzumab); Polivy® (polatuzumab vedotin-piiq); Tarceva® (erlotinib); RozlytrekTM (entrectinib); Tecentriq® (atezolizumab); Venclexta®/Venclyxto® (venetoclax); Xeloda® (capecitabine); Zelboraf® (vemurafenib). Furthermore, the Roche Group has a robust investigational oncology pipeline focusing on new therapeutic targets and novel combination strategies. For more